Rezolute (RZLT) News Today $4.39 +0.16 (+3.78%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Rezolute, Inc. (NASDAQ:RZLT) Given Consensus Recommendation of "Buy" by AnalystsRezolute, Inc. (NASDAQ:RZLT - Get Free Report) has been given a consensus rating of "Buy" by the eight analysts that are currently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy rating. The average 12-month target price among brokerages thatDecember 21 at 4:46 AM | marketbeat.comDaron Evans Buys 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockDecember 19 at 8:44 AM | insidertrades.comInsider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 10,000 Shares of StockRezolute, Inc. (NASDAQ:RZLT - Get Free Report) CFO Daron Evans purchased 10,000 shares of the company's stock in a transaction that occurred on Wednesday, December 18th. The stock was purchased at an average price of $4.29 per share, for a total transaction of $42,900.00. Following the purchase, the chief financial officer now owns 150,900 shares in the company, valued at $647,361. This represents a 7.10 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.December 18 at 8:03 PM | marketbeat.comInsider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Acquires 9,000 Shares of StockDecember 13, 2024 | insidertrades.comRezolute (NASDAQ:RZLT) versus BetterLife Pharma (OTCMKTS:PVOTF) Critical AnalysisDecember 12, 2024 | americanbankingnews.comRezolute’s Erodsetug: A Promising Universal Treatment for Severe Refractory Hypoglycemia with Strong Growth PotentialDecember 5, 2024 | markets.businessinsider.comRezolute reports inducement award under Nasdaq listing ruleDecember 5, 2024 | markets.businessinsider.comRezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)December 5, 2024 | globenewswire.comRezolute announces U.S. FDA granted ODD to ersodetugDecember 3, 2024 | markets.businessinsider.comRezolute: Ersodetug Downstream Tech Could Ignite The Hyperinsulinism MarketDecember 3, 2024 | seekingalpha.comFDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor HyperinsulinismDecember 3, 2024 | markets.businessinsider.comRezolute's Ersodetug Gets Orphan Drug Designation To Treat Hypoglycemia Due To Tumor HyperinsulinismDecember 3, 2024 | markets.businessinsider.comRezolute, Inc. Advances Late-Stage Trials for Rare Disease TherapiesNovember 26, 2024 | markets.businessinsider.comRezolute, Inc. (NASDAQ:RZLT) Receives Average Recommendation of "Buy" from BrokeragesShares of Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) have been given an average rating of "Buy" by the eight ratings firms that are covering the stock, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerNovember 26, 2024 | marketbeat.comIs Rezolute, Inc. (RZLT) the Best Multibagger Stock to Buy Heading into 2025?November 16, 2024 | msn.comRezolute’s Promising Growth: Buy Rating Backed by Financial and Clinical AdvancementsNovember 9, 2024 | markets.businessinsider.comPromising Developments and Strong Financial Position Justify Buy Rating for RezoluteNovember 9, 2024 | markets.businessinsider.comRezolute’s Promising Pipeline and Financial Stability Drive Buy Rating and Increased Price TargetNovember 9, 2024 | markets.businessinsider.comRezolute’s Strategic Progress and Financial Resilience Justify Buy RatingNovember 9, 2024 | markets.businessinsider.comRezolute (NASDAQ:RZLT) Earns Buy Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $14.00 target price on shares of Rezolute in a report on Friday.November 8, 2024 | marketbeat.comRezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business UpdateNovember 8, 2024 | markets.businessinsider.comWedbush Predicts Rezolute's Q1 Earnings (NASDAQ:RZLT)Rezolute, Inc. (NASDAQ:RZLT - Free Report) - Stock analysts at Wedbush issued their Q1 2025 earnings per share estimates for shares of Rezolute in a report issued on Monday, November 4th. Wedbush analyst Y. Zhong anticipates that the company will post earnings per share of ($0.44) for the quarterNovember 7, 2024 | marketbeat.comWedbush Initiates Coverage of Rezolute (RZLT) with Outperform RecommendationNovember 6, 2024 | msn.comRezolute initiated with an Outperform at WedbushNovember 5, 2024 | markets.businessinsider.comRezolute (NASDAQ:RZLT) Given Outperform Rating at WedbushWedbush reissued an "outperform" rating and issued a $112.00 target price on shares of Rezolute in a research note on Monday.November 4, 2024 | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Given Average Rating of "Buy" by BrokeragesShares of Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) have earned a consensus recommendation of "Buy" from the seven ratings firms that are presently covering the stock, Marketbeat reports. Seven analysts have rated the stock with a buy rating. The average 12 month price target among brokeragesNovember 1, 2024 | marketbeat.comWith 62% ownership, Rezolute, Inc. (NASDAQ:RZLT) boasts of strong institutional backingOctober 17, 2024 | finance.yahoo.comRezolute, Inc. (NASDAQ:RZLT) Stock Position Reduced by Renaissance Technologies LLCRenaissance Technologies LLC decreased its stake in Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 45.3% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 180,421 shares of the company's stock afOctober 8, 2024 | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Receives Average Recommendation of "Buy" from AnalystsRezolute, Inc. (NASDAQ:RZLT - Get Free Report) has been given an average rating of "Buy" by the seven ratings firms that are presently covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that haveOctober 7, 2024 | marketbeat.comEdward Nash Recommends Buy on Rezolute, Sets $9 Target Amidst Product Progress and Regulatory AdvancementsOctober 5, 2024 | markets.businessinsider.comMarshall Wace LLP Acquires New Shares in Rezolute, Inc. (NASDAQ:RZLT)Marshall Wace LLP bought a new position in Rezolute, Inc. (NASDAQ:RZLT - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,047,230 shares of the company's stock, valued at approximately $4,503,000. MarshOctober 2, 2024 | marketbeat.comBuy Rating Affirmed for Rezolute on Strong Clinical Progress and Strategic Pipeline DevelopmentSeptember 28, 2024 | markets.businessinsider.comRezolute (NASDAQ:RZLT) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $14.00 target price on shares of Rezolute in a research note on Friday.September 27, 2024 | marketbeat.comAffinity Asset Advisors LLC Acquires 250,000 Shares of Rezolute, Inc. (NASDAQ:RZLT)Affinity Asset Advisors LLC lifted its holdings in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 15.6% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,850,000 shares of the company's stock after buying an additional 250,000September 25, 2024 | marketbeat.comInsider Buying: Rezolute, Inc. (NASDAQ:RZLT) Director Buys 4,259 Shares of StockSeptember 25, 2024 | insidertrades.comJMP Securities Reiterates "Market Outperform" Rating for Rezolute (NASDAQ:RZLT)JMP Securities restated a "market outperform" rating and issued a $7.00 target price on shares of Rezolute in a research report on Friday.September 20, 2024 | marketbeat.comRezolute, Inc.: Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business UpdateSeptember 20, 2024 | finanznachrichten.deRezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business UpdateSeptember 19, 2024 | globenewswire.comRezolute, Inc. (NASDAQ:RZLT) Shares Bought by Federated Hermes Inc.Federated Hermes Inc. lifted its holdings in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 11.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,279,327 shares of the company's stocSeptember 15, 2024 | marketbeat.comRezolute (NASDAQ:RZLT) Price Target Raised to $15.00 at BTIG ResearchBTIG Research lifted their price target on Rezolute from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Tuesday.September 10, 2024 | marketbeat.comPeninsula drug maker plots late-stage clinical trial after FDA lifts delaySeptember 10, 2024 | bizjournals.comFDA Gives Green Signal To Rezolute's Genetic Disorder TreatmentSeptember 9, 2024 | benzinga.comRezolute’s RZ358 Advances: FDA Clearance and Positive Trial Outlook Justify Buy RatingSeptember 9, 2024 | markets.businessinsider.comRezolute Buy Rating Affirmed: RZ358 Clinical Advancements and Strong Market PotentialSeptember 9, 2024 | markets.businessinsider.comRezolute rises as FDA lifts clinical hold on hyperinsulinism therapySeptember 9, 2024 | msn.comRezolute's (RZLT) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $14.00 price target on shares of Rezolute in a report on Monday.September 9, 2024 | marketbeat.comUS FDA lifts partial clinical hold on Rezolute's blood sugar treatmentSeptember 9, 2024 | reuters.comFDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 StudySeptember 9, 2024 | globenewswire.comRezolute to Participate in Upcoming Investor ConferencesAugust 28, 2024 | markets.businessinsider.comGuggenheim Initiates Coverage of Rezolute (RZLT) with Buy RecommendationAugust 28, 2024 | msn.com Get Rezolute News Delivered to You Automatically Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW RZLT Media Mentions By Week RZLT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RZLT News Sentiment▼1.600.60▲Average Medical News Sentiment RZLT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RZLT Articles This Week▼42▲RZLT Articles Average Week Get Rezolute News Delivered to You Automatically Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AVDL News COLL News SEPN News ZYME News BCAX News GYRE News PSTX News PAHC News COGT News NUVB News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RZLT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rezolute With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
